Elicio Therapeutics (ELTX) Free Cash Flow (2020 - 2026)
Elicio Therapeutics posted quarterly Free Cash Flow of -$11.6 million for Q1 2026, down 15.08% year-on-year from -$13.7 million in Q1 2025, and down 70.92% on a QoQ basis from -$6.8 million in Q4 2025.
Elicio Therapeutics (ELTX) has 7 years of Free Cash Flow data on file, last reported at -$11.6 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow fell 15.08% year-over-year to -$11.6 million; the trailing twelve-month figure through Mar 2026 stood at -$38.5 million (down 9.51% YoY), and the FY2025 full-year result was -$37.0 million, up 0.5% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$11.6 million, down from -$6.8 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $5.6 million in Q2 2022 and bottomed at -$15.7 million in Q1 2022.
- The 5-year median for Free Cash Flow is -$9.0 million (2025), against an average of -$8.3 million.
- The widest annual swing landed in 2022, when Free Cash Flow jumped 151.76%; it then sank 269.97% in 2023.
- A 5-year view of Free Cash Flow shows it stood at -$7.4 million in 2022, then slumped by 34.24% to -$9.9 million in 2023, then gained by 11.18% to -$8.8 million in 2024, then advanced by 22.48% to -$6.8 million in 2025, then plunged by 70.92% to -$11.6 million in 2026.
- The last three Free Cash Flow figures came in at -$11.6 million (Q1 2026), -$6.8 million (Q4 2025), and -$11.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Elicio Therapeutics | 217.63 Mn | 202.68 Mn | - | -11.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -11.65 Mn |
| Mar 31, 2026 | -11.65 Mn |
| Dec 31, 2025 | -6.81 Mn |
| Dec 31, 2025 | -6.81 Mn |
| Sep 30, 2025 | -11.09 Mn |
| Sep 30, 2025 | -11.09 Mn |
| Jun 30, 2025 | -8.95 Mn |
| Jun 30, 2025 | -8.95 Mn |
| Mar 31, 2025 | -10.12 Mn |
| Mar 31, 2025 | -10.12 Mn |
| Dec 31, 2024 | -8.79 Mn |
| Dec 31, 2024 | -8.79 Mn |
| Sep 30, 2024 | -7.27 Mn |
| Sep 30, 2024 | -7.27 Mn |
| Jun 30, 2024 | -8.97 Mn |
| Jun 30, 2024 | -8.97 Mn |
| Mar 31, 2024 | -12.12 Mn |
| Mar 31, 2024 | -12.12 Mn |
| Dec 31, 2023 | -9.90 Mn |
| Dec 31, 2023 | -9.90 Mn |
| Sep 30, 2023 | -5.23 Mn |
| Sep 30, 2023 | -5.23 Mn |
| Jun 30, 2023 | -9.48 Mn |
| Jun 30, 2023 | -9.48 Mn |
| Mar 31, 2023 | -8.16 Mn |
| Mar 31, 2023 | -8.16 Mn |
| Dec 31, 2022 | -7.37 Mn |
| Dec 31, 2022 | -7.37 Mn |
| Sep 30, 2022 | -5.39 Mn |
| Sep 30, 2022 | -5.39 Mn |
| Jun 30, 2022 | 5.58 Mn |
| Jun 30, 2022 | 5.58 Mn |
| Mar 31, 2022 | -15.65 Mn |
| Mar 31, 2022 | -15.65 Mn |
| Dec 31, 2021 | -14.02 Mn |
| Dec 31, 2021 | -14.02 Mn |
| Sep 30, 2021 | -15.26 Mn |
| Sep 30, 2021 | -15.26 Mn |
| Jun 30, 2021 | -10.78 Mn |
| Jun 30, 2021 | -10.78 Mn |
| Mar 31, 2021 | -12.59 Mn |
| Mar 31, 2021 | -12.59 Mn |
| Dec 31, 2020 | 20.59 Mn |
| Dec 31, 2020 | 20.59 Mn |
| Sep 30, 2020 | -21.91 Mn |
| Sep 30, 2020 | -21.91 Mn |
| Jun 30, 2020 | -12.81 Mn |
| Jun 30, 2020 | -12.81 Mn |
| Mar 31, 2020 | -8.75 Mn |
| Mar 31, 2020 | -8.75 Mn |